Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $43.1 million.

  • Heron Therapeutics' Cash & Equivalents rose 6731.28% to $43.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.1 million, marking a year-over-year increase of 6731.28%. This contributed to the annual value of $25.8 million for FY2024, which is 1002.55% down from last year.
  • Per Heron Therapeutics' latest filing, its Cash & Equivalents stood at $43.1 million for Q3 2025, which was up 6731.28% from $16.5 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Cash & Equivalents peaked at $191.2 million during Q2 2021, and registered a low of $13.5 million during Q2 2023.
  • Over the past 5 years, Heron Therapeutics' median Cash & Equivalents value was $28.7 million (recorded in 2023), while the average stood at $49.8 million.
  • Per our database at Business Quant, Heron Therapeutics' Cash & Equivalents surged by 13681.13% in 2021 and then plummeted by 8303.09% in 2022.
  • Quarter analysis of 5 years shows Heron Therapeutics' Cash & Equivalents stood at $90.5 million in 2021, then tumbled by 83.03% to $15.4 million in 2022, then surged by 86.65% to $28.7 million in 2023, then decreased by 10.03% to $25.8 million in 2024, then skyrocketed by 66.92% to $43.1 million in 2025.
  • Its Cash & Equivalents stands at $43.1 million for Q3 2025, versus $16.5 million for Q2 2025 and $19.3 million for Q1 2025.